REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Lymphokine > Interleukin InterleukinInterleukin patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.08/16/07 - 20070190025 - Method to enhance hematopoiesis The present invention relates generally to the fields of immunology and molecular biology, and particularly to a method for treating hematopoietic disorders. The invention provides a method to treat a deficiency of one or more types of blood cells in a mammal, which includes administering an effective amount of TISF ... 08/16/07 - 20070190024 - Il-11 muteins The present invention relates to new IL-11 muteins of which site I hydrophobocity has been increased. These muteins act as IL-11 agonist or hyperagonist, and are notably useful as anti-thrombocytopenia agents, and as agents improving the resistance of an organism to the deleterious in vivo effects induced by radiation or ... 08/09/07 - 20070184024 - Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors The invention encompasses compounds of Formula I, pharmaceutically acceptable salts thereof, compositions, and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. ... 08/09/07 - 20070184023 - Method for down-regulation of vegf The present invention provides for novel immunogenic variants of VEGF (vascular endothelial growth factor) which are useful in active specific immunotherapy against diseases that are characterized by overexpression of VEGF. The invention also relates to methods of treating such diseases (for instance cancer) as well as to various tools in ... 08/09/07 - 20070184022 - Microsome vaccine A vaccine composition is provided which comprises inverted microsomes or fragments thereof from an animal cell in association with an externally disposed peptide antigen and a protein of the MHC. ... 08/09/07 - 20070184021 - Use of caspase inhibitors as a therapeutic agent against radiation-induced injury The present invention provides methods for the treatment of radiation-induced injury by providing to a subject a caspase inhibitor. The caspase inhibitor may be provided before or after the radiation injury, and further may be provided in combination with a second caspase inhibitor, an anti-apoptotic molecule, a radioprotectant, a cytokine ... 08/02/07 - 20070178063 - Methods of treating cancer using il-21 and monoclonal antibody therapy Methods for treating cancer by co-administering a therapeutic monoclonal antibody with IL-21 are described. Exemplary monoclonal antibodies that can be used are rituximab, trastuzumab and anti-CTLA-4 antibodies. The enhanced antitumor of the combination therapy is particularly useful for patient populations that are recalcitrant to monoclonal therapy, relapse after treatment with ... 07/26/07 - 20070172458 - Il-6/il-6r fusion protein The present invention relates to a fusion protein comprising a functional IL-6 molecule and a functional DS-sIL-6R molecule. The present invention also relates to a nucleic acid encoding the fusion protein, methods for producing the fusion protein and the use of the fusion protein in the treatment of infectious diseases ... 07/26/07 - 20070172457 - Interleukins-21 and 22 The present invention relates to novel human proteins designated Interleukin-21 (IL-21) and Interleukin-22 (IL-22), and isolated polynucleotides encoding these proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing these human proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, and/or preventing ... 07/26/07 - 20070172456 - Il-1 zeta, il-1 zeta splice variants and xrec2 dnas and polypeptides The invention is directed to novel, purified and isolated IL-1 zeta and Xrec2 polypeptides and fragments thereof, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and uses thereof. ... 07/26/07 - 20070172455 - Chimeric interleukin-6 soluble receptor/ligand protein, analogs thereof and uses thereof Chimeric proteins constructed from the fusion of the naturally occurring form of the soluble IL-6 receptor and IL-6 which are useful for treatment of cancer and liver disorders, enhancement of bone marrow transplantation, and treatment of other IL-6 related conditions are provided. ... 07/26/07 - 20070172454 - Use of il-6/il-6 chimera in huntington's disease The invention relates to the use of an IL-6R/IL-6 chimera, a mutein, isoform, fused protein, functional derivative, active fraction or circularly permutated derivative or a salt thereof, for the manufacture of a medicament for the treatment and/or prevention of Huntington's disease. ... 07/26/07 - 20070172453 - Tolerogenic approach for type 1 diabetes The present invention provides compositions and methods for the treatment and prevention of type I diabetes. ... 07/26/07 - 20070172452 - Methods for treating viral infection using il-28 and il-29 IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof ... 07/26/07 - 20070172451 - Methods for treating viral infection using il-28 and il-29 IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof ... 07/19/07 - 20070166282 - Homogeneous preparations of il-28 and il-29 Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity ... 07/12/07 - 20070160579 - Methods of modulating a mammalian cytokine Provided are methods of modulating cytokine activity, e.g., for the purpose of treating immune and inflammatory disorders, including tumors and cancer. Also provided are methods of administering agonists or antagonists of IL-33 and IL-33 receptor. ... 07/12/07 - 20070160578 - Expansion of natural killer and cd8 t-cells with il-15r/ligand activator complexes The disclosure provides methods, and compositions for use in methods, for expanding lymphocyte populations in vitro, ex vivo, and in vivo using IL-15Rα/IL-15 activator complexes. ... 07/12/07 - 20070160577 - Interleukin-11 compositions and methods of use The present invention provides methods for the treatment and/or prevention of thrombocytopenia including thrombocytopenia associated with drug-induced liver damage and thrombocytopenia associated with drug-induced bone marrow destruction. The methods of treatment of the invention include administration of interleukin-11 to a subject suffering from or susceptible to thrombocytopenia and/or receiving or ... 07/12/07 - 20070160576 - Il-17a/f heterologous polypeptides and therapeutic uses thereof The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present ... 07/05/07 - 20070154453 - Interleukin-12p40 variants with improved stability Modified interleukin-12 (IL-12) p40 polypeptides are disclosed. The modified polypeptides have alterations in the IL-12p40 subunit to eliminate the protease site between positions Lys260 and Arg261. The modified IL-12p40 polypeptides according to the invention have improved stability compared to wild-type mature human IL-12p40 polypeptides. ... 07/05/07 - 20070154452 - Therapeutic agent for pancreas cancer The present invention is aiming to provide further advantageous effects on treating pancreas cancer, thus providing the means therefor is the subject. The present invention was obtained by finding that there were differences in prognosis in accordance with intrinsic IL-12-producing ability when Novel Immunotherapy for Cancer (NITC) was conducted in ... 07/05/07 - 20070154451 - Enhancer of anticancer activity in viral therapy and method of preventing or treating cancer The present invention provides a pharmaceutical that safely and effectively enhances the anticancer activity of viral therapy and particularly the antitumor immunity of viral therapy. The present invention also provides a method of preventing or treating cancer that uses this drug. The anticancer activity enhancer according to the present invention ... 06/21/07 - 20070141026 - Immunotherapy in cancer treatment The present invention relates to a novel method of cancer immuno-therapy and to a kit for use in this method. Specifically, the present invention relates to a novel method of collecting lymphocytes from sentinel lumph nodes and in vitro culture for the multiplication thereof lymphocytes. ... 06/07/07 - 20070128161 - Methods of treating cancer using il-21 Methods for treating mammals with cancer using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a ... 06/07/07 - 20070128160 - Methods for treating viral infection using il-28 and il-29 IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof ... 05/31/07 - 20070122383 - Interleukin-10 compositions for the treatment of adenocarcinomas The present invention is directed to methods for the treatment of adenocarcinomas that are characterized by the overexpression of a particular oncogene, Pim-1. The procedure involves administering a therapeutically effective amount of interleukin-10 that has been coupled to a carrier that increases its circulating plasma half-life. ... 05/31/07 - 20070122382 - Methods of treating cancer using il-21 and monoclonal antibody therapy Methods for treating cancer by co-administering a therapeutic monoclonal antibody with IL-21 are described. Exemplary monoclonal antibodies that can be used are rituximab, trastuzumab and anti-CTLA-4 antibodies. The enhanced antitumor of the combination therapy is particularly useful for patient populations that are recalcitrant to monoclonal therapy, relapse after treatment with ... 05/17/07 - 20070110714 - Medicinal composition for treatment of chronic hepatitis c The present invention provides a pharmaceutical composition for treating chronic hepatitis C characterized by comprising at least one active ingredient selected from the group consisting of IL-15, myeloid dendritic cell maturation stimulators (for example, CpG oligo deoxynucleotide, GM-CSF, IL-4, LPS, CD40L, polyI:C, TNF-a and IFN-?) and lectin-binding substances (for example, ... 05/17/07 - 20070110713 - Novel multifunctional cytokines The present invention relates to a novel fusion protein with the formula X—Y, or Y—X, wherein X represents a first immunoregulating polypeptide and Y represents a second immunoregulating polypeptide different from X. The present invention also relates to a nucleic acid molecule encoding such a fusion protein and a vector ... 05/10/07 - 20070104681 - Isolated nucleic acid molecules which encode a soluble il-tif/il-22 receptor or binding protein which binds to il-tif/il-22, and uses thereof The invention relates to soluble proteins which bind to the molecule known as IL-TIF/IL-22. The proteins can antagonize the effect of IL-TIF/IL-22 on target cells. The nucleic acid molecules encoding the proteins, and uses of the protein, are also described. ... 05/03/07 - 20070098686 - Use of apoptotic cells ex vivo to generate regulatory t cells The present invention provides a method of generating T cells with regulatory activity by incubating leukocytes with autologous apoptotic peripheral blood mononuclear cells. ... 05/03/07 - 20070098685 - Methods and kits to treat chronic inflammatory immune diseases by administering a proteasome inhibitor and an interleukin 2 receptor agonist Methods and kits for treatment of immune diseases with an IL2 receptor agonist and a proteasome inhibitor are provided. ... 05/03/07 - 20070098684 - Methods of reducing aggregation of il-1ra Methods of reducing aggregation of an aggregating IL-1ra comprising incubating IL-1ra with at least one accessory molecule are provided. Kits comprising IL-1ra and at least one accessory molecule are also provided. Pharmaceutical compositions comprising IL-1ra and at least one accessory molecule are also provided. ... 04/19/07 - 20070086980 - Methods of treating cancer using il-21 Methods for treating mammals with cancer using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a ... 04/12/07 - 20070081974 - Antibody targeting osteoclast-associated protein The present invention relates to a method of detecting metabolic bone disorders using a gene expressed at a high level in osteoclasts, a method of screening for a compound effective for treatment and/or prevention of metabolic bone disorders, and a pharmaceutical composition for treatment and/or prevention of metabolic bone disorders. ... 03/29/07 - 20070071719 - Compositions and methods for regulation of tumor necrosis factor-alpha The present invention relates to compositions and methods relating to an interleukin18-inducible cytokine termed tumor necrosis factor-alpha inducing factor (TAIF) or interleukin-32 (IL-32). In particular, the present invention provides compositions and methods for treating autoimmune diseases and cancer, in part by regulation of tumor necrosis factor-alpha expression. ... 03/22/07 - 20070065406 - Homogeneous preparations of il-28 and il-29 Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity ... 03/22/07 - 20070065405 - Uses of human zven proteins and polynucleotides The present invention provides methods of using Zven1 and Zven2 polypeptides to increase chemokine production. The present invention also provides methods for treating intestinal motility disorders and improving gastrointestinal function with Zven1 and Zven2 polypeptides. ... 03/22/07 - 20070065404 - Uses of humans zven proteins and polynucleotides The present invention provides methods of using Zven1 and Zven2 polypeptides to increase chemokine production. The present invention also provides methods for treating intestinal motility disorders and improving gastrointestinal function with Zven1 and Zven2 polypeptides. ... 03/22/07 - 20070065403 - Uses of human zven proteins and polynucleotides The present invention provides methods of using Zven1 and Zven2 polypeptides to increase chemokine production. The present invention also provides methods for treating intestinal motility disorders and improving gastrointestinal function with Zven1 and Zven2 polypeptides. ... 03/22/07 - 20070065402 - Methods for treating viral infection using il-28 and il-29 IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof ... 03/22/07 - 20070065401 - Methods for treating viral infection using il-28 and il-29 IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof ... 03/22/07 - 20070065400 - Treatment of tumor metastases and cancer Tumor metastases in cancer patients are inhibited by administration of a combination therapy including effective amounts of Interleukin-2 and a methylol transfer agent such as taurolidine, taurultam or mixtures thereof. ... 03/22/07 - 20070065399 - Use of colostrinin, constituent peptides thereof, and analogs thereof as modulators of intracellular signaling molecules The present invention provides methods that utilize compositions containing colostrinin, a constituent peptide thereof, an active analog thereof, and combinations thereof, as modulators of intracellular signaling molecules, for example. ... 03/15/07 - 20070059284 - Methods of treating infections using il-21 Methods for treating mammals with infections, particularly viral infections using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be ... 03/15/07 - 20070059283 - Feline il-18 nucleic acid molecules The present invention relates to canine and feline proteins. In particular, the present invention discloses feline interleukin-18, feline caspase-1, feline interleukin-12 single chain and canine interleukin-12 single chain proteins. The present invention also includes feline interleukin-18, feline caspase-1, feline interleukin-12 single chain and canine interleukin-12 single chain nucleic acid molecules ... 03/08/07 - 20070053875 - Homogeneous preparations of il-28 and il-29 Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity ... 03/08/07 - 20070053874 - Methods for treating viral infection using il-28 and il-29 IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof ... 03/08/07 - 20070053873 - Canine tumor treatment method, pharmaceutical formulation applied thereto, and method of cryogenically preserving cells used therewith A treatment for tumorous canines and a method of preparing, cultivating, and cryogenically preserving the pharmaceutical formulation used in the treatment. Canine lymphocytes are activated and expanded in the presence of a combination of anti-canine CD3 antibodies and interleukin-2 (IL-2) (preferably anti-canine CD3 antibodies and human interleukin-2 (human IL-2)) and ... 03/08/07 - 20070053872 - Treatment of wounds using il-17b IL-17B is known to stimulate the proliferation of chondrocytes, bone, and is highly expressed in nervous tissue, resulting in repair of diseased tissue. When IL-17B is absent a marked negative effect on wound healing is noted. The present invention comprises providing IL-17B, by topical, parental, or other administration means, in ... 03/01/07 - 20070048277 - Homogeneous preparations of il-28 and il-29 Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity ... 03/01/07 - 20070048276 - Homogeneous preparations of il-28 and il-29 Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity ... 03/01/07 - 20070048275 - Homogeneous preparations of il-28 and il-29 Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity ... 03/01/07 - 20070048274 - Homogeneous preparations of il-28 and il-29 Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity ... 03/01/07 - 20070048273 - Methods of treating cancer using il-21 Methods for treating mammals with cancer using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a ... 03/01/07 - 20070048272 - Methods of treating cancer using il-21 Methods for treating mammals with cancer using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a ... 03/01/07 - 20070048271 - Methos of treating cancer using il-21 Methods for treating mammals with cancer using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a ... 03/01/07 - 20070048270 - Methods of treating cancer using il-21 Methods for treating mammals with cancer using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a ... 03/01/07 - 20070048269 - Methods of treating cancer using il-21 Methods for treating mammals with cancer using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a ... 03/01/07 - 20070048268 - Methods of treating cancer using il-21 Methods for treating mammals with cancer using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a ... 03/01/07 - 20070048267 - Methods of treating cancer using il-21 Methods for treating mammals with cancer using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a ... 03/01/07 - 20070048266 - Methods of treating cancer using il-21 Methods for treating mammals with cancer using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a ... 03/01/07 - 20070048265 - Methods of treating autoimmune diseases using il-21 Administration of IL-21 results in decreasing autoimmune responses and thereby provides a beneficial treatment for autoimmune diseases. Specific autoimmune diseases that may be treated include multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, psoriasis, ankylosing spondilitis, scleroderma, Type I diabetes, psoriatic arthritis, osteoarthritis, inflammatory bowel disease, atopic dermatitis and asthma. Pharmaceutical ... 03/01/07 - 20070048264 - Methods of treating cancer using il-21 and monoclonal antibody therapy Methods for treating cancer by co-administering a therapeutic monoclonal antibody with IL-21 are described. Exemplary monoclonal antibodies that can be used are rituximab, trastuzumab and anti-CTLA-4 antibodies. The enhanced antitumor of the combination therapy is particularly useful for patient populations that are recalcitrant to monoclonal therapy, relapse after treatment with ... 03/01/07 - 20070048263 - Il-21 production in prokaryotic hosts The expression vectors and methods using an E. coli expression system for the large scale production of IL-21 are described. The vectors utilize the IL-21 coding sequence with specific changes in nucleotides in order to optimize codons and mRNA secondary structure for translation in E. coli. Using the expression vectors, ... 03/01/07 - 20070048262 - Methods for treating viral infection using il-28 and il-29 IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof ... 03/01/07 - 20070048261 - Vaccine comprising il-12 or il-23 for treatment of autoimmune diseases The present invention provides improved vaccines and immunogenic compositions comprising IL-12 or IL-23, and processes for the preparation of such vaccines and immunogenic compositions. ... 02/22/07 - 20070041940 - Methods of treating cancer using il-21 Methods for treating mammals with cancer using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a ... 02/08/07 - 20070031376 - Il-6 receptor. il-6 direct fusion protein The present invention intends to provide an IL-6R•IL-6 fusion protein and the like in which IL-6R and IL-6 are directly linked without a linker. The IL-6 receptor•IL-6 fusion protein of the present invention has a structure in which one amino:acid residue constituting IL-6 receptor and one amino acid residue constituting ... 02/08/07 - 20070031375 - Il-16 antagonist peptides and dna encoding the peptides The present invention has found that a series of peptides having sequences that substantially correspond to specific regions of the C-terminus of IL-16 can inhibit the activity of IL-16. The present invention has demonstrated that such IL-16-inhibiting peptides can be as short as 4 amino acid in length. Based on ... 02/08/07 - 20070031374 - Combination therapy The invention provides combination treatments with IL-21, analogues and derivatives thereof. ... 02/01/07 - 20070025962 - Interleukin-8 homologous polypeptides and therapeutic uses thereof The present invention is directed to novel polypeptides having structural homology to IL-8 and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies ... 02/01/07 - 20070025961 - Composition for stabilizing survival of transplanted hematopoietic stem cell, kit for obtaining the composition, method of stabilizing survival of transplanted hematopoietic stem cell, human monoclonal antibody or human polyclonal antibody and method of p [PROBLEMS] To stabilize the survival of transplanted hematopoietic stem cells by using HLA identical activated lymphocytes. [MEANS FOR RESOLVING PROBLEMS] HLA identical activated lymphocytes in mononuclear cells separated from peripheral blood or umbilical cord blood are proliferated and activated. After separating and collecting, the HLA identical activated lymphocytes are employed ... 02/01/07 - 20070025960 - Bisphosphonates for prophylaxis and therapy against bioterrorism agents Disclosed is a method of activating γ/δ T cells to provide temporary protection against a broad spectrum of infectious biological threats to the military and support personnel and exposed persons. γ/δ T cells are activated by administration of high doses of bisphosphonates. ... 01/25/07 - 20070020233 - Use of il-12 and il-12 antagonists in the treatment of autoimmune diseases Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-γ or TNF-α. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid ... 01/18/07 - 20070014765 - Methods for treating renal cell carcinoma Methods for treating renal cell carcinoma using low doses of IL-2 are disclosed. In particular, the invention relates to methods of treating metastatic renal cell carcinoma in patients who are renally impaired and/or intolerant of high dose IL-2 therapy. The therapeutic regimen described herein significantly inhibits tumor growth with reduced ... 01/18/07 - 20070014764 - Reduction in myocardial infarction size This invention provides methods and compositions used for reducing the Myocaidial Infarct (MI) size in diabetic subjects exhibiting the haptoglobin (Hp) 2 allele. Specifically, the invention relates to reduction of MI in diabetic subjects carrying the Hp-2 allele by reducing the oxidative sterss in these subjects following ischemia-reperfusion injury. ... 01/11/07 - 20070009479 - Methods for treating dermatitis using mutant human il-4 compositions Methods of administering a therapeutically effective amount of a mutant human IL-4 composition to a human subject for the amelioration and treatment of dermatitis, including contact and atopic dermatitis. ... 01/04/07 - 20070003515 - Method of inducing memory b cell development and terminal differentiation A method is disclosed herein for inducing differentiation of a B cell progenitor into a memory B cells and/or a plasma cell. The method includes contacting a population of cells including a mature B cell or a B cell progenitor with an effective amount of IL-21, and isolating memory B ... 12/28/06 - 20060292116 - Interleukin-2 mutants with reduced toxicity Interleukin-2 (IL-2) mutants having reduced toxicity, which include full-length IL-2, truncated forms of IL-2 and forms of IL-2 that are linked to another molecule are disclosed herein. Particular substitutions within IL-2, particularly within the permeability enhancing peptide region of IL-2 achieve substantial reduction of vasopermeability activity as compared to a ... 12/28/06 - 20060292115 - Methods and compositions for treating and preventing inflammatory conditions Methods of treating eosinophilia by down regulating eotaxin and at least one other Th-2 related cytokine are dislosed as are multivalent immunogenic compositions that generate an active immune response in a subjet comprising autoantibodies to eotaxin-1, eotaxin-2, IL-4, IL-5, IL-9, and IL-13 and treatment methods using such compositions. ... 12/07/06 - 20060275259 - Il-8-like proteins This invention relates to proteins, termed INSP093, herein identified as secreted proteins, in particular, as members of the Interleukin (IL) 8-like chemokine family and to the use of these proteins and nucleic acid sequences from the encoding genes in the diagnosis, prevention and treatment of disease. ... 11/30/06 - 20060269515 - Interleukin-2 muteins Novel human interleukin-2 (IL-2) muteins or variants thereof, and nucleic acid molecules and variants thereof are provided. Methods for producing these muteins as well as methods for stimulating the immune system of an animal are also disclosed. In addition, the invention provides recombinant expression vectors comprising the nucleic acid molecules ... 11/30/06 - 20060269514 - Methods and compositions for the modulation of immune responses and cancer diseases Disclosed is a method of treating, preventing or ameliorating disease using a chimeric protein comprising a cell-binding region and a biologically active region such as a toxin or other cytostatic or cytocidal molecule. The present invention discloses using a chimeric protein to modulate immune response to effectuate improvement in disease. ... 11/16/06 - 20060257362 - Method and composition for preventing and reating solid tumors Compositions and methods of preventing or treating a breast cancer are disclosed. The composition and method can utilize an endothelin B agonist and a chemotherapeutic agent as active ingredients to treat a solid tumor in mammals, including humans. Alternatively, the composition and method can utilize an endothelin B antagonist and ... 11/16/06 - 20060257361 - Novel form of interleukin-15, fc-il-15, and methods of use The present invention relates to Fc-IL-15 hybrids, which may or may not include peptide linkers between the IL-15 and the Fc portion, for methods of treatment of tumors and viral infections. The IL-15 hybrids can be Fc-IL-15 or IL-15-Fc hybrids. The Fc-IL-15 hybrids include variants, including the IL-15 and Fc ... 11/09/06 - 20060251617 - Methods for treating lymphomas Methods for treating B-cell lymphomas, such as non-Hodgkin's lymphoma (NHL) are disclosed. The methods use a combination therapy of a chemotherapeutic agent, an IL-2 and, optionally, an anti-CD20 antibody. ... 11/02/06 - 20060246032 - Chimeric il-10 Disclosed are chimeric proteins having a cytokine fused to an enzymatically inactive polypeptide which increases the circulating half-life of the cytokine. The chimeric proteins are useful for treating, inhibiting, or preventing a variety of conditions, including septic shock, granulomatous disorders, Type I diabetes, and various cancers (e.g., multiple myeloma) in ... 10/19/06 - 20060233751 - Regulatory t cells suppress autoimmunity The invention provides methods for producing an autoantigen-specific regulatory T cell enriched composition, and resultant compositions and methods of use. ... 10/19/06 - 20060233750 - Materials and method of modulating the immune response Methods and materials to modulate the immune response to treat or prevent a disease, including methods of making T helper-antigen presenting cells and methods of using these cells. The invention also relates to methods of making exosome-absorbed dendritic cells and the uses of these cells to modulate the immune response ... 10/19/06 - 20060233749 - Interleukin-19 The present invention concerns a novel human cytokine. In particular, isolated nucleic acid molecules are provided encoding interleukin-19 (IL-19). IL-19 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The IL-19 polypeptides of the present invention can also be used to raise polyclonal ... 10/19/06 - 20060233748 - Mimetics of interleukin-8 and methods of using them in the prevention, treatment, diagnosis, and ameliorization of symptoms of a disease The present invention teaches compositions and uses of mimetics of IL-8 in the diagnosis, prevention, treatment, and ameliorization of symptoms of a variety of diseases. ... 10/12/06 - 20060228331 - Il-21 derivatives and variants The invention provides derivatives of IL-21 or variants thereof, methods of producing such variants, new variants of IL-21, and various methods of using such molecules. ... 10/05/06 - 20060222628 - Gallium complexes of 3-hydroxy-4-pyrones to treat infection by intracellular prokaryotes and dna viruses Methods are provided for treating or preventing infections by obligate intracellular prokaryotes, including mycoplasma, rickettsia and chlamydia, and DNA viruses, including herpes viruses, papillomaviruses, adenoviruses and hepatitis B virus. The methods involve the administration of 3:1 complexes of 3-hydroxy-4-pyrones with gallium, e.g., gallium maltolate. Therapies incorporating gallium maltolate in combination ... 10/05/06 - 20060222627 - Optimizing pharmacodynamics of therapeutic agents for treating vascular tissue An implant such as a stent is coated with a biodegradable or non-biodegradable polymer having therein an antiproliferative/immunosuppressive agent and a compound which reduces the rate of metabolism of the antiproliferative/immunosuppressive agent thereby inhibiting restenosis. ... 09/21/06 - 20060210534 - Pegylated interleukin-10 Interleukin-10 (IL-10) conjugated via a linker to one or more polyethylene glycol (PEG) molecules at a single amino acid residue of the IL-10, and a method for preparing the same, are provided. The method produces a stable mono-pegylated IL-10, which retains IL-10 activity, where pegylation is selective for the N-terminus ... 09/21/06 - 20060210533 - Compounds and compositions for delivering active agents Oxadiazole compounds and compositions for the delivery of active agents are provided. Methods of administration and preparation are provided as well. ... 09/07/06 - 20060198822 - Treatment for multiple sclerosis It is disclosed herein that particular forms of MS have significant pathogenetic differences both between each other and when compared to controls. In particular, CD127 is under-expressed in one form of MS but over-expressed in another form, relative both to each form of MS and to controls. Methods and compositions ... 09/07/06 - 20060198821 - Elevation of adenosine level by cytokine-induced expression of cd73 This invention concerns a method of inducing an elevated level of adenosine in an individual by administering to said individual an effective amount of either i) recombinant protein CD73 or ii) a cytokine or another factor-being capable of inducing endothelial CD73 expression, or a combination thereof. Furthermore, the invention concerns ... 08/24/06 - 20060188476 - Interleukin 20 (il-20) and its use in neovascularisation The invention provides a novel method of regulating neovascularisation. ... 08/24/06 - 20060188475 - Methods and compositions using immunomodulatory compounds for the treatment of immunodeficiency disorders Methods of treating, preventing and/or managing an immunodeficiency disease or disorder are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active agent. Methods of boosting humoral immunity are also disclosed. ... 08/24/06 - 20060188474 - Interleukin 1beta protease and interleukin 1beta protease inhibitors wherein R1 and R3 are independently any D or L isomer amino acid, R2 is Ala or Gly, and wherein the specific protease cleavage site is between Asp and R2. Inhibitor compounds, compositions and methods for inhibiting Interleukin 1β protease activity are also disclosed. The inhibitor compounds comprise an amino ... 08/17/06 - 20060182714 - Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides The invention provides synthesis and application of new structural well defined branched polymers as protraction agents for peptide and protein. ... 08/17/06 - 20060182713 - Vaccine composition comprising interleukin-15 (il-15) Vaccine composition containing IL-15 for active immunization to treatment diseases related to over-expression of this cytokine. The technical aim pursued in this invention is to inhibit IL-15 activity through development of a therapeutic vaccine which elicits IL-15 neutralizing antibodies in the immunized host. IL-15 can be presented in this vaccine ... 08/10/06 - 20060177422 - Method for preparing a physiologically active il-18 polypeptide The present invention provides a method for producing physiologically active human Interleukin-18 (“IL-18”). ... 08/10/06 - 20060177421 - Treatment of allergic conditions by use of il 21 The invention relates to the administration of IL-21 for management, treatment and prevention of diseases or conditions where eosinophils are involved in a protective response e.g. allergic reactions, allergic diseases, allergic conditions and parasites diseases. ... 08/10/06 - 20060177420 - Use of dendritic cells (dcs) expressing interleukin 12 (il-12) The present invention discloses the use of active dendritic cells (DCs) releasing interleukin 12 (IL-12) which are loaded with an antigen against a specific pathogen or a specific tumor and, due to the treatment with lipopolysaccharide (LPS) and interferon-gamma (IFN-γ), release IL-12, for the preparation of a medicament for treating ... 07/27/06 - 20060165653 - Use of fc receptor polymorphisms as diagnostics for treatment strategies for immune-response disorders Methods for the use of Fc gamma receptor (FcγR) polymorphisms as a diagnostic for intervention with interleukin-2 (IL-2) immunotherapy are provided. The methods comprise detecting the allelic pattern of an FcγRIIIA gene or FcγRIIA gene of an individual, and determining whether the allelic pattern is predictive of a positive therapeutic ... 07/27/06 - 20060165652 - Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy A method of promoting the regression of a cancer in a mammal comprising: (i) administering to the mammal nonmyeloablative lymphodepleting chemotherapy, and (ii) subsequently administering: (a) autologous T-cells, which have been previously isolated, selected for highly avid recognition of an antigen of the cancer, the regression of which is to ... 07/20/06 - 20060159657 - Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders Therapeutic formulations comprising an effective amount of IL-2 or other lymphokine and a biodegradable polymeric carrier having reverse gelation properties and the methods of use thereof for local or both local and systemic control of proliferative cell disorders is disclosed. The formulation can be administered intratumorally/peritumorally and forms an IL-2 ... 07/20/06 - 20060159656 - Formulations for il-11 Provided by the present invention are novel compositions and methods for obtaining concentrated preparations of IL-11 and formulations of IL-11 suitable for storage and administration. ... 07/20/06 - 20060159655 - Treating immunological disorders using agonists of interleukin-21 / interleukin-21 receptor Methods and compositions for modulating interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using agonists of IL-21 or IL-21 receptor (“IL-21R” or “MU-1”), are disclosed. IL-21/IL-21R agonists can be used by themselves or in combination with anti-inflammatory agents to treat, e.g., ameliorate, symptoms associated with immunological disorders of the nervous system, e.g., multiple ... 07/06/06 - 20060147417 - Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use The present invention relates to isolated immunogens and their use in the treatment of diseases that are treatable with neutralization of IL-13, such as COPD, asthma and atopic disorders such as hayfever, contact allergies and atopic dermatitis. In particular the invention relates to the neutralization of the biological effects of ... 06/29/06 - 20060140906 - Composition comprising cysteamine for improving immunity of animals There is provided a new use of cysteamine, a salt thereof, or a composition containing cysteamine or a salt thereof, for improving immunity of animals. ... 06/15/06 - 20060127357 - Rapamycin and il-10 for the treatment of immune diseases The invention discloses a combined preparation containing IL-10 and rapamucin able to induce immunosuppression and antigen-specific immune tolerance, and the use thereof in the treatment of diseases involving an excessive, dysfunctional or uncontrolled immune response mediated by T cells. ... 06/08/06 - 20060120997 - Cancer therapeutic compositions A pharmaceutical composition comprising lectins is anti-tumorigenic. The composition is used in imaging, diagnosis and therapy of cancer. ... 06/01/06 - 20060115452 - Uses of interleukin-18 for treating skin disorders associated with uv radiations The present invention relates to uses of interleukin-18. ... 05/18/06 - 20060104945 - Enhancement of b cell proliferation by il-15 Compositions and methods for modulating the growth, proliferation, and/or differentiation of B-cells in the germinal center are disclosed, and include use of IL-15 inhibitors, antagonists, and agonists. The compositions and methods find use in treating B-cell-related disorders, including neoplasms of the B-cell lineage. ... 05/18/06 - 20060104944 - Activators and inhibitors of protease activated receptor2 (par2) and methods of use The present invention relates to a method of treating a subject for a condition mediated by a deficiency in angiogenesis by administering to the subject a PAR2 agonist under conditions effective to promote angiogenesis and treat the conditions mediated by a deficiency in angiogenesis. A further aspect of the present ... 05/18/06 - 20060104943 - Vaccine comprising il-13 and an adjuvant The present invention relates to IL-13 vaccines and their use in the treatment of diseases that are treatable with neutralization of IL-13 such as COPD, asthema and atopic disorders such as hayfever, contact allergies and atopic dermatitis. The vaccines of the present invention comprise an IL-13 immunogen and an adjuvant ... 05/04/06 - 20060093576 - Stabilized liquid polypeptide-containing pharmaceutical compositions Stabilized liquid polypeptide-containing pharmaceutical compositions are provided. The compositions comprise an amino acid base, which serves as the primary stabilizing agent of the polypeptide, and an acid and/or its salt form to buffer the solution within an acceptable pH range for stability of the polypeptide. Methods for increasing stability of ... 04/20/06 - 20060083713 - Methods of using a human il-17 related polypeptide to treat disease Methods are provided for the treatment or prevention of atherosclerosis, allergic autoimmune diseases, endothelial cell apoptosis, allograft vasculopathy, hypertension, congestive heart failure, ischemia/reperfusion injury, type 1 diabetes, inflammation, immunodeficiencies, cancers, and infectious diseases by administering a human IL-17 related polypeptide and/or an antibody recognizing an epitope thereof to a patient ... 03/30/06 - 20060067912 - Methods for the induction of professional and cytokine-producing regulatory t cells The field of the invention is generally related to methods used for the induction of T cells with suppressive activity. More specifically, the methods are used to generate professional regulatory T cells and cytokine-producing T cells with enhanced suppressive activity. ... 03/23/06 - 20060062760 - Use of interleukin-11 to prevent immune-mediated cytotoxicity The use of interleukin-11 to prevent, to ameliorate, and to treat an immune-mediated disease in a mammal in need of such treatment is disclosed. ... 03/16/06 - 20060057103 - Antagonists of interleukin-15 Antagonists of mammalian interleukin-15 (“IL-15”) are disclosed and include muteins of IL-15 and modified IL-15 molecules that are each capable of binding to the IL-15Rα-subunit and that are incapable of transducing a signal through either the β- or γ-subunits of the IL-15 receptor complex. Also included are monoclonal antibodies against ... 03/16/06 - 20060057102 - Mutant interleukin-15-containing compositions and suppression of an immune response The invention features methods of treating patients who have received, or who are scheduled to receive, a heart, lung, or heart-lung transplant by administering to the patient an agent that antagonizes IL-15 or the IL-15 receptor (IL-15R). ... 02/23/06 - 20060039892 - Methods of healing wounds by administering human il-18 The present invention relates generally to the use of human IL-18, also known as interferon-γ-inducing factor (IGIF), in the treatment of skin wounds, surgical wounds, leg ulcers, diabetic ulcers, gastrointestinal mucositis, oral mucositis, and lung injury. ... 02/16/06 - 20060034800 - Method for treatment of drug addiction and for screening of pharmaceutical agents therefor The present invention is directed to a method for treatment of drug addiction and screening methods for identifying pharmaceutical agents that ameloriate or prevent the deleterious effects of addition. The invention is as well directed to a group of genes and a group of gene products that are up or ... 02/02/06 - 20060024269 - Use of il-28 and il-29 to treat cancer and autoimmune disorders Methods for treating patients with cancer and autoimmune disorders using IL-28 and IL-29 molecules. The IL-28 and IL-29 molecules include polypeptides that have homology to the human IL-28 or IL-29 polypeptide sequence and proteins fused to a polypeptide with IL-28 and IL-29 functional activity. The molecules can be used as ... 02/02/06 - 20060024268 - Modulation of immunoglobulin production and atopic disorders An IL-21 polypeptide or other IL-21 pathway agonist can be used to treat atopic disorders, e.g., asthma. ... 01/26/06 - 20060018873 - Peptides of il-2 and derivatives thereof and their use as therapeutic agents The present invention relates to new peptides of IL-2, and derivatives thereof and their use as therapeutic agents. ... 01/19/06 - 20060013802 - Techniques to treat neurological disorders by enhancing the presence of anti-inflammatory mediators Methods and devices to enhance anti-inflammatory effects in the CNS to treat neurological, neurodegenerative, neuropsychiatric disorders, pain and brain injury are described. Anti-inflammatory enhancing agents that target IL-10 production and signal transduction pathways are discussed. Devices described include therapy delivery devices comprising a reservoir capable of housing an anti-inflammatory enhancing ... 01/19/06 - 20060013801 - Prevention of and therapy for radiation toxicity of normal tissues using drugs which block il-1 activity A method for the prevention of and therapy for radiation pneumonitis, dermatitis, soft tissue fibrosis and central nervous system toxicity in patients undergoing therapeutic radiation. In addition, the invention provides for pre-treatment of those responding to nuclear bio terrorism or other nuclear or radiological accidents. Thus, with the present invention, ... 01/12/06 - 20060008446 - Methods for treating pain Methods of treating pain by delivery of anti-inflammatory cytokines, proinflammatory cytokine antagonists, and agents that act to reduce or prevent proinflammatory cytokine actions, to the nervous system are described. These agents can be delivered using gene therapy techniques. Alternatively, the agents can be delivered in protein compositions. ... 01/05/06 - 20060002891 - Cytomodulating conjugates of members of specific binding pairs Novel conjugates are provided comprising a moiety capable of specifically binding to a target cell joined to a selective moiety for binding to an endogenous effector agent, capable of causing cell inactivation or cytotoxicity. Example of conjugates are a ligand for a surface membrane protein, e.g. IL-2 receptor, joined to ... 12/08/05 - 20050271619 - Isolated nucleic acid molecules which encode t cell inducible factors, or interleukin-21, the proteins encoded, and uses thereof The invention involves isolation of nucleic acid molecules, the expression of which are upregulated by interleukin-9. The amino acid sequences of the proteins which correspond to the nucleic acid molecules show some structural features of cytokines. In addition to the nucleic acid molecules and the proteins, various uses of the ... 12/08/05 - 20050271618 - Methods of reducing aggregation of il-1ra Methods of reducing aggregation of an aggregating IL-1ra comprising incubating IL-1ra with at least one accessory molecule are provided. Kits comprising IL-1ra and at least one accessory molecule are also provided. Pharmaceutical compositions comprising IL-1ra and at least one accessory molecule are also provided. ... 12/01/05 - 20050265966 - Methods of treating cancer using il-21 and monoclonal antibody therapy Methods for treating cancer by co-administering a therapeutic monoclonal antibody with IL-21 are described. Exemplary monoclonal antibodies that can be used are rituximab, trastuzumab and anti-CTLA-4 antibodies. The enhanced antitumor of the combination therapy is particularly useful for patient populations that are recalcitrant to monoclonal therapy, relapse after treatment with ... 11/10/05 - 20050249701 - Il-7 drug substance, composition, preparation and uses The present invention relates, generally, to the fields of immunology and molecular biology. The invention discloses, more particularly, new and improved interleukin-7 drug substances, corresponding specific immunoreactive antibodies, as well as compositions comprising the same, their preparation and uses. The invention also discloses methods to characterize the impurity profile of ... 11/03/05 - 20050244372 - Interleukin-3 (il-3) multiple mutation polypeptides The present invention relates to recombinant human interleukin-3 (hIL-3) variant or mutant proteins (muteins). These hIL-3 muteins contain amino acid substitutions and may also have amino acid deletions at both the N- and C-termini. The invention also relates to pharmaceutical compositions containing the hIL-3 muteins and methods for using them. ... 10/27/05 - 20050238620 - Compositions and methods for suppressing fibrocyte differentiation from monocytes and for detecting fibrocyte differentiation The present invention relates to the ability of SAP to suppress the differentiation of monocytes into fibrocytes. It also relates to the ability of IL-12, laminin-1, cross-linked IgG and IgG aggregates to suppress the differentiation of monocytes into fibrocytes. Methods and compositions for suppressing differentiation of monocytes into fibrocytes using ... 10/06/05 - 20050220761 - Use of il6r/il6 chimera in nerve cell regeneration The present invention provides for the use of IL6R/IL6 chimera for the manufacture of medicaments for the treatment of neurological diseases and disorders. ... 09/22/05 - 20050208018 - Use of calreticulin and calreticulin fragments to inhibit endothelial cell growth and angiogenesis, and suppress tumor growth Methods for inhibiting endothelial cell growth and angiogenesis, and suppressing tumor growth using calreticulin, fragments of calreticulin and variants of calreticulin are provided. Such methods are useful for the treatment of cancer and diseases associated with unwanted angiogenesis, for example chronic retinal detachment. ... 09/15/05 - 20050201979 - Interleukin-2 mutants with reduced toxicity Interleukin-2 (IL-2) mutants having reduced toxicity, which include full-length IL-2, truncated forms of IL-2 and forms of IL-2 that are linked to another molecule are disclosed herein. Particular substitutions within IL-2, particularly within the permeability enhancing peptide region of IL-2 achieve substantial reduction of vasopermeability activity as compared to a ... 09/15/05 - 20050201978 - Tumor and infectious disease therapeutic compositions A pharmaceutical composition comprising lectins is anti-tumorigenic and anti-viral, bacterial or protozoan. The composition, termed BiOmune is also useful for imaging, diagnosis and therapy of cancer. ... 09/01/05 - 20050191274 - Immunologic activities of rhesus cytomegalovirus encoded il-10 and human cytomegalovirus encoded il-10 The present invention is provides pharmaceutical compositions and prophylactic and therapeutic methods of treatment for immune disorders using rhesus or human CMV IL-10. The invention is useful for inhibiting lymphocyte proliferation and underlying cellular events both in vitro and in vivo. ... 08/25/05 - 20050186176 - Compounds and compositions for delivering active agents Modified amino acid compounds useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well. ... 08/18/05 - 20050180952 - Methods for intradermal delivery of therapeutics agents The present invention relates to methods and devices for delivering one or more biologically active agents, particularly therapeutic agents, to the intradermal compartment of a subject's skin. The present invention provides an improved method of delivery of biologically active agents, such as therapeutic agents, through lymphatic vasculature accessed by intradermal ... 08/18/05 - 20050180951 - Combined immunotherapy of fusion cells and interleukin-12 for treatment of cancer The present invention relates to methods and treatment protocols for the immunotherapy of cancer by administering a therapeutically effective dose of fusion cells formed by fusion of autologous dendritic cells and autologous non-dendritic cells in combination with interleukin-12. ... 08/11/05 - 20050175584 - Functionalized colloidal metal compositions and methods The present invention comprises methods and compositions for making functionalized/reactive colloidal metal compositions and the uses thereof. The present invention comprises compositions and methods for delivery systems of agents, including therapeutic compounds, pharmaceutical agents, drugs, detection agents, nucleic acid sequences and biological factors. In general, these vector compositions comprise a ... 08/11/05 - 20050175583 - Methods and compositions for the production of monoclonal antibodies The present invention comprises compositions and methods for making monoclonal antibodies. The present invention further comprises vectors that replicate the immune system components, particularly an antigen-presenting cell (APC) element of the immune synapse. Additionally, the present invention may further comprise synthetic T-cells. ... 07/28/05 - 20050163750 - Methods of preventing aggregation of various substances upon rehydration or thawing and compositions obtained thereby The present invention encompasses methods to prevent aggregation of a wide variety of substances during freezing/thawing and/or dehydrating/rehydrating. The substances thus obtained and compositions comprising the substances are also encompassed by the invention. ... 07/28/05 - 20050163749 - Method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture This invention relates to a breakthrough method for pre-sensitizing cancer prior to a therapeutic treatment such as chemotherapy, radiation therapy or immuno-therapy and a novel cytokine mixture used in the method thereof. The cytokine mixture is a serum-free and mitogen-free mixture comprised of specific ratios of cytokines such as IL-1β, ... 07/21/05 - 20050158276 - Il-12 an adjuvant for bordetella pertussis vaccines This invention provides a composition of at least one Bordetella antigen and an effective adjuvant amount of interleukin-12 (IL-12), and uses thereof as a vaccine against Bordetella infection. Methods for using IL-12 as an adjuvant in combination with vaccines against Bordetella are also provided. ... 07/21/05 - 20050158275 - Method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture This invention relates to a breakthrough method for pre-sensitizing cancer prior to a therapeutic treatment such as chemotherapy, radiation therapy or immuno-therapy and a novel cytokine mixture used in the method thereof The cytokine mixture is a serum-free and mitogen-free mixture comprised of specific ratios of cytokines such as IL-1β, ... 06/30/05 - 20050142108 - Methods of modulating cytokine activity; related reagents Provided are methods of modulating cytokine activity, e.g., for the purpose of treating inflammation of the airways and lung. Also provided are reagents for use in screening for agonists or antagonists of IL-19 or IL-24. ... 06/30/05 - 20050142107 - Use of il-6-type cytokines for maturation of oocytes The use of certain IL-6-type cytokines for the in vitro maturation of mammalian oocytes is described. The in vitro matured oocytes may be used in in vitro fertilization protocols. ... 06/30/05 - 20050142106 - Mutant interleukin-2 (il-2) polypeptides The present invention relates to IL-2 mutants with increased affinity for the IL-2 alpha-receptor subunit (IL-2Rα). The invention thus includes IL-2 mutants with improved biological potency. The invention also includes methods for directed evolution of IL-2α using yeast surface display to generate mutants with increased affinity for IL-2Rα. ... 06/30/05 - 20050142105 - Chimeric molecule for the treatment of th2-like cytokine mediated disorders The invention provides uses and methods for alleviating respiratory tract symptoms of allergy, asthma, and of viral, bacterial, fungal and parasitic infections by shifting inappropriate TH2 responses to TH1 responses by administering IL-13 receptor-targeted immunotoxins to the respiratory tract. ... 06/23/05 - 20050136034 - Uses of il-12 in hematopoiesis Embodiments of the present invention are directed to uses of Interleukin-12 (IL-12) in enhancing or stimulating hematopoiesis to yield hematopoietic recovery in a mammal in need. Particular embodiments of the invention are directed to uses of IL-12 as an adjuvant therapy to alleviate the hematopoietic toxicities associated with one or ... 06/16/05 - 20050129658 - Topical formulation for delivery of interleukin-11 Provided by the present invention are topical formulations of Interleukin-11 and methods for treating a variety of disorders, including inflammatory bowel diseases (e.g., Crohn's disease, ulcerative colitis, indeterminate colitis, and infectious colitis), mucositis (e.g., oral mucositis, gastrointestinal mucositis, nasal mucositis, and proctitis), necrotizing enterocolitis, inflammatory skin disorders (e.g., psoriasis, atopic ... 06/09/05 - 20050123509 - Modulating charge density to produce improvements in the characteristics of spray-dried proteins Methods are provided for preparing spray-dried, drug-containing particles comprising the steps of selecting (i) a drug and an optional excipient, wherein the combination of the drug and optional excipient has an effective pI, and (ii) an aqueous solution having a pH that is different from the effective pI; (b) combining ... ### FreshPatents.com Support |